Kinnate Biopharma Stock (NASDAQ: KNTE) stock price, news, charts, stock research, profile.
Open | $2.660 |
Close | - |
Volume / Avg. | 38.211K / 374.369K |
Day Range | 2.660 - 2.690 |
52 Wk Range | 1.040 - 7.185 |
Market Cap | $124.991M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 67 |
Short Interest | 3.6% |
Days to Cover | 8.64 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Kinnate Biopharma (NASDAQ: KNTE) through any online brokerage.
Other companies in Kinnate Biopharma’s space includes: Molecular Partners (NASDAQ:MOLN), Vincerx Pharma (NASDAQ:VINC), Anixa Biosciences (NASDAQ:ANIX), Vistagen Therapeutics (NASDAQ:VTGN) and Sangamo Therapeutics (NASDAQ:SGMO).
The latest price target for Kinnate Biopharma (NASDAQ: KNTE) was reported by Stifel on Monday, February 26, 2024. The analyst firm set a price target for 2.59 expecting KNTE to fall to within 12 months (a possible -3.36% downside). 14 analyst firms have reported ratings in the last year.
The stock price for Kinnate Biopharma (NASDAQ: KNTE) is $2.68 last updated Today at March 28, 2024 at 11:06 AM EDT.
There are no upcoming dividends for Kinnate Biopharma.
Kinnate Biopharma’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Kinnate Biopharma.
Kinnate Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.